Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare disease treatment, with a foundation in hematology and cellular metabolism. Its lead product, mitapivat (PYRUKYND/AQVESME), is a pyruvate kinase activator approved for PK deficiency and thalassemia. The pipeline includes tebapivat (LR-MDS, SCD), AG-181 (PKU), and AG-236 (polycythemia vera), an siRNA licensed from Alnylam Pharmaceuticals.
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001439222-26-000025 | EDGAR | 87K words |
| 2025-02-13 | 2024-12-31 | 0001439222-25-000009 | EDGAR | 87K words |
| 2024-02-15 | 2023-12-31 | 0001439222-24-000035 | EDGAR | 87K words |
| 2023-02-23 | 2022-12-31 | 0001439222-23-000039 | EDGAR | 85K words |
| 2022-02-24 | 2021-12-31 | 0001439222-22-000024 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001439222-21-000029 | EDGAR | — |
| 2020-02-19 | 2019-12-31 | 0001439222-20-000014 | EDGAR | — |
| 2019-02-14 | 2018-12-31 | 0001439222-19-000004 | EDGAR | — |
| 2018-02-14 | 2017-12-31 | 0001439222-18-000004 | EDGAR | — |
| 2017-02-16 | 2016-12-31 | 0001193125-17-046795 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-30 | 2026-06-30 | 0001439222-26-000118 | EDGAR | 42K words |
| 2025-10-30 | 2025-09-30 | 0001439222-25-000116 | EDGAR | 44K words |
| 2025-07-31 | 2025-06-30 | 0001439222-25-000089 | EDGAR | 43K words |
| 2025-05-01 | 2025-03-31 | 0001439222-25-000036 | EDGAR | 44K words |
| 2024-10-31 | 2024-09-30 | 0001439222-24-000138 | EDGAR | 47K words |
| 2024-08-01 | 2024-06-30 | 0001439222-24-000121 | EDGAR | 46K words |
| 2024-05-02 | 2024-03-31 | 0001439222-24-000069 | EDGAR | 44K words |
| 2023-11-02 | 2023-09-30 | 0001439222-23-000140 | EDGAR | 47K words |
| 2023-08-03 | 2023-06-30 | 0001439222-23-000119 | EDGAR | 47K words |
| 2023-05-04 | 2023-03-31 | 0001439222-23-000065 | EDGAR | 44K words |
| 2022-11-03 | 2022-09-30 | 0001439222-22-000099 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001439222-22-000070 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-30 | 0001439222-26-000115 | EDGAR | 3K words |
| 2026-02-12 | 0001439222-26-000023 | EDGAR | 2K words |
| 2026-01-12 | 0001439222-26-000018 | EDGAR | 2K words |
| 2025-10-30 | 0001439222-25-000114 | EDGAR | 3K words |
| 2025-08-04 | 0001439222-25-000090 | EDGAR | 1K words |
| 2025-07-31 | 0001439222-25-000087 | EDGAR | 2K words |
| 2025-07-08 | 0001439222-25-000076 | EDGAR | 1K words |
| 2025-06-18 | 0001193125-25-142745 | EDGAR | 1K words |
| 2025-05-01 | 0001439222-25-000034 | EDGAR | 2K words |
| 2025-02-13 | 0001439222-25-000007 | EDGAR | 3K words |
220 total filings indexed. 188 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001439222 |
| Ticker | AGIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.agios.com |
| Listed | 2013-07-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AGIO (~200 tokens, structured JSON with cryptographic provenance)